You may know its surveys, but there’s more to its market intelligence Daniel has 10+ years of experience reporting on investments and personal finance for outlets like AARP Bulletin and ...

Johnson & Johnson (NYSE:JNJ) fell ~3% in early trading on Wednesday, marking its biggest intraday drop since July 2023, even as the healthcare giant posted better-than-expected financials for Q4 ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...

The order questions that the 14th Amendment extends citizenship automatically to anyone born in the United States. President Donald Trump moved to end a decades-old immigration policy known as ...

Peter Andre is back from Australia after spending some quality time with his parents. Since arriving back in the UK, the Mysterious Girl singer has been busy with more filming but it means he ...

He was appointed in August 2012 and retained by voters in 2016. Peter J. Maassen was retained in the Alaska Supreme Court, Maassen's seat election with 57.47% of the vote. Alaska Supreme Court, ...

Liz Giuffre does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Peter Andre is the epitome of a family man but in a new interview, the star has made a surprising announcement about the future of his household with wife Emily MacDonagh, 35, and five kids. The ...

“We have gotten tons of people pulling over to take pictures, bringing their kids to take photos in front of it,” said Allyssa Hardiman, co-owner of St. Lawrence Nurseries. It took a big team ...

A legal spat needn’t spell trouble for the prospect of Sasaki-mania arising in San Diego. As the Padres have recruited Japanese ace pitcher Roki Sasaki in anticipation of a decision that could ...

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...